|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7020 EUR | +8.33% |
|
+23.37% | -54.30% |
| 13/07 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 11/07 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 59.71M | |
| 29.28x | 6.09x | -0.73x | 5.36x | 22.26x | 30.13x | 2.65% | 316B | |
| 24.88x | 2.1x | -12.8x | 3.38x | 11.92x | 20.05x | 1.6% | 73.28B | |
| 12.48x | 13.11x | 0.08x | 6.33x | 9.65x | 10.59x | - | 9.87B | |
| 15.86x | 1.37x | 0.77x | 1.99x | 6.75x | 8.15x | 2.85% | 8.15B | |
| 21.29x | 5.65x | 2.14x | 6.02x | 17.05x | 17.76x | -.--% | 4.38B | |
| 36.73x | 2.4x | -1.7x | 2.34x | 27.37x | 41.97x | 0.75% | 3.91B | |
| 31.1x | - | 0.2x | 5.92x | 16.92x | 27.42x | - | 3.62B | |
| -135.16x | - | 2.55x | - | - | - | -.--% | 2.51B | |
| 63x | - | -0.12x | - | - | - | - | 1.26B | |
| 14.06x | 0.81x | -0.82x | 1.03x | 7.49x | 25.6x | 4.4% | 1.02B | |
| -69x | 1.67x | 1.04x | - | - | - | - | 930M | |
| 41.14x | 6.45x | -1.07x | 13.56x | 28.47x | 33.49x | - | 928M | |
| Average | 7.14x | 4.41x | -0.87x | 5.10x | 16.43x | 23.91x | 1.75% | 32.77B | |
| Weighted average by Cap. | 26.78x | 5.40x | -2.71x | 4.96x | 19.79x | 27.45x | 2.41% |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
